Unknown

Dataset Information

0

Navigating next-generation HR+/HER2- metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression.

ABSTRACT:

SUBMITTER: Neven P 

PROVIDER: S-EPMC11093079 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Navigating next-generation HR<sup>+</sup>/HER2<sup>-</sup> metastatic breast cancer therapies: a critical commentary on abemaciclib <i>vs.</i> tucidinostat after palbociclib progression.

Neven Patrick P   Dullens Lieke L   Han Sileny S   Deblander Anne A   Van Herck Yannick Y   Van Houdt Maxime M   Wildiers Hans H  

Translational breast cancer research : a journal focusing on translational research in breast cancer 20231023

Similar Datasets

Unknown Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2- advanced breast cancer: A multicenter retrospective study.
| S-EPMC12702079 | biostudies-literature
Unknown Real-world comparative effectiveness of first-line abemaciclib versus palbociclib in HR+/HER2- metastatic breast cancer: A propensity-matched retrospective analysis.
| S-EPMC12550314 | biostudies-literature
Unknown First-line therapy with palbociclib in patients with advanced HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: The real-life study PALBOSPAIN.
| S-EPMC11182794 | biostudies-literature
Unknown Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28).
| S-EPMC11653472 | biostudies-literature
Unknown First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.
| S-EPMC4517534 | biostudies-literature
Unknown Efficacy and safety of palbociclib plus endocrine therapy for patients with HR<sup>+</sup>/HER2<sup>-</sup> advanced breast cancer in real-world clinical practice.
| S-EPMC9011297 | biostudies-literature
Unknown Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR&lt;sup&gt;+&lt;/sup&gt;/HER2&lt;sup&gt;-&lt;/sup&gt;advanced breast cancer.
| S-EPMC12809096 | biostudies-literature
Unknown Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
| S-EPMC5818877 | biostudies-literature
Unknown Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.
| S-EPMC9637121 | biostudies-literature
Unknown Targeting ferroptosis resistance resensitizes metastatic HR&lt;sup&gt;+&lt;/sup&gt;HER2&lt;sup&gt;-&lt;/sup&gt; breast cancer cells to palbociclib-hormone therapy.
| S-EPMC11999879 | biostudies-literature